{"code":"E79.0","type":"code","title":"Hyperuricemia without signs of inflammatory arthritis and tophaceous disease","codeAlso":[],"includes":[],"modern_v":"official26","codeFirst":[],"excludes1":["Ataxia-telangiectasia (Q87.19)","Bloom's syndrome (Q82.8)","Cockayne's syndrome (Q87.19)","calculus of kidney (N20.0)","combined immunodeficiency disorders (D81.-)","Fanconi's anemia (D61.09)","gout (M1A.-, M10.-)","orotaciduric anemia (D53.0)","progeria (E34.8)","Werner's syndrome (E34.8)","xeroderma pigmentosum (Q82.1)","androgen insensitivity syndrome (E34.5-)","congenital adrenal hyperplasia (E25.0)","hemolytic anemias attributable to enzyme disorders (D55.-)","Marfan syndrome (Q87.4-)","5-alpha-reductase deficiency (E29.1)"],"excludes2":["Ehlers-Danlos syndromes (Q79.6-)"],"isBillable":true,"fyEffectivity":{"fy2026":true,"fy2027":true},"sibling_codes":["E79","E79.1","E79.2","E79.8","E79.81","E79.82","E79.89","E79.9"],"inclusionTerms":["Asymptomatic hyperuricemia"],"sibling_titles":{"code":"E79.9","title":"Disorder of purine and pyrimidine metabolism, unspecified","isBillable":true},"useAdditionalCode":[],"clinicalDefinition":"Hyperuricemia without signs of inflammatory arthritis and tophaceous disease is a billable ICD-10-CM diagnosis code (E79.0). Inclusion terms: Asymptomatic hyperuricemia. Excludes1 (not coded here): Ataxia-telangiectasia (Q87.19); Bloom's syndrome (Q82.8); Cockayne's syndrome (Q87.19); calculus of kidney (N20.0); combined immunodeficiency disorders (D81.-); Fanconi's anemia (D61.09); gout (M1A.-, M10.-); orotaciduric anemia (D53.0); progeria (E34.8); Werner's syndrome (E34.","officialDefinition":"Hyperuricemia without signs of inflammatory arthritis and tophaceous disease is a billable ICD-10-CM diagnosis code (E79.0). Inclusion terms: Asymptomatic hyperuricemia. Excludes1 (not coded here): Ataxia-telangiectasia (Q87.19); Bloom's syndrome (Q82.8); Cockayne's syndrome (Q87.19); calculus of kidney (N20.0); combined immunodeficiency disorders (D81.-); Fanconi's anemia (D61.09); gout (M1A.-, M10.-); orotaciduric anemia (D53.0); progeria (E34.8); Werner's syndrome (E34.8); xeroderma pigmentosum (Q82.1); androgen insensitivity syndrome (E34.5-); congenital adrenal hyperplasia (E25.0); hemolytic anemias attributable to enzyme disorders (D55.-); Marfan syndrome (Q87.4-); 5-alpha-reductase deficiency (E29.1). Excludes2 (not included here): Ehlers-Danlos syndromes (Q79.6-).","seventhCharacterInstructions":[],"workflowProtocols":[],"guidelines":{"whenToUse":[],"whenNotToUse":[],"commonBillingMistakes":[],"codeComparisons":[],"documentationChecklist":[]},"domainLandscape":{"summary":"Primary diagnostic domain and clinical landscape evaluation.","keyCategories":[],"diagnosticContinuum":"Progression continuum from acute presentation to resolution."},"children":[],"hierarchy":[],"relatedCodes":[],"relevantCPTCodes":[],"documentationTips":[],"caseStudies":[],"description":"","overview":""}